Please login to the form below

Not currently logged in
Email:
Password:

Accenture and BMS launch Indian pharmacovigilance centre

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

The new centre will process and code of adverse event data and generate regulatory periodic and aggregate reports on safety, as well as physician medical review of adverse events. Over 140 Accenture employees will run the site.

Pharmacovigilance involves monitoring safety data, assessment and reporting of potential side effects of approved medicines.

According to Accenture and BMS, the jv is the first of its kind involving a collaboration for 'end-to-end' safety case processing.

The team is organised as a parallel process and extension of the BMS pharmacovigilance headquarters' operations, which will handle data and reports between the two companies.

Part of a multi-year R&D agreement signed in April 2007, the jv will aid BMS's in its efforts to expand R&D operations in India as part of the company's global strategy.

Dr John Balian, senior vice-president of global pharmacovigilance and epidemiology at BMS, said: "Working with Accenture, we will continue to access world-class talent to deliver on our regulatory obligations, while enhancing our focus on patient safety."

Eric Sandor, managing director of Accenture Pharmacovigilance Services, added: "Through a truly collaborative partnership with BMS, we have established an industry leading operation that is delivering substantial efficiency and improved flexibility for the company's pharmacovigilance organisation."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics